Neurophet announced on the 10th that it will raise a total of 32 billion won in new investment through the issuance of convertible redeemable preferred shares (CPS) and convertible bonds (CB). This is the first fundraising since it secured 28 billion won through its KOSDAQ listing in July last year.
The company held a board meeting that day and approved a plan to raise a total of 32 billion won by issuing 16 billion won each in CPS and CB. Major domestic asset management firms, including GVA Asset Management, Pine Value Asset Management, Orion Asset Management, Focus Asset Management, and Welcome Asset Management, will participate in this investment.
The funds raised will be focused on expanding in global markets. The company plans to use the funds to expand collaboration with global big pharma and medical institutions, build an on-the-ground business infrastructure in the United States, and strengthen overseas sales and marketing. In particular, it plans to accelerate business expansion centered on the U.S. and Japanese markets.
Founded in 2016, Neurophet is an artificial intelligence (AI)-based brain imaging analysis company that has commercialized solutions and therapeutic medical devices covering the entire cycle of "diagnosis–treatment guide–treatment." Its main businesses include AI solutions for analyzing degenerative brain diseases such as Alzheimer's disease, imaging contract research organization (CRO) services that support new drug development, and brain electrical stimulation therapy solutions for stroke rehabilitation and depression treatment.
Co-CEO Bin Jun-gil said, "As the Alzheimer's disease therapeutics market enters a full-fledged growth phase, demand for related medical AI solutions is also rising rapidly," and added, "Based on this investment, we will proactively respond to global market expansion and carry out aggressive sales centered on the United States and Japan."